Stock Financial Ratios, Dividends, Split History
WAB / Wabtec Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||7,824.57|
|Enterprise Value ($M)||9,481.37|
|Book Value ($M)||2,969.12|
|Book Value / Share||30.84|
|Price / Book||2.79|
|NCAV / Share||-14.77|
|Price / NCAV||-6.80|
|Preferred Stock Shares Outstanding||0|
|Basic Weighted Average Common Shares Outstanding And Non Vested Restricted Stock Expected To Vest||95,740,000|
|Common Stock Shares Outstanding||96,034,352|
|Common Shares Outstanding||96,090,518|
|Weighted Average Number Of Shares Outstanding Basic||95,453,000|
|Weighted Average Number Of Diluted Shares Outstanding||96,125,000|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||0.06|
|Return on Assets (ROA)||0.04|
|Return on Equity (ROE)||0.12|
|Identifiers and Descriptors|
|Central Index Key (CIK)||943452|
|929740908 092974010 929740958 011540104|
|SIC 3743 - Railroad Equipment|
Stock splits are used by Wabtec Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Related News Stories
Just a few days ago, J.P. Morgan analyst Stephen Tusa suggested industrial giant General Electric Company (NYSE:GE) should be — if it wasn’t — mulling the possibility of yet another dividend cut. Though the payout is important to a wide swath of GE stock owners, it arguably isn’t the best use of income for a cash-strapped, debt-laden company, he says. (16-0)
After a several long, frustrating weeks of going nowhere the transportation sector is finally moving forward. Held back by the under-performing airline stocks, the Dow Jones Transportation Average (DJTA) was confined to a narrow lateral range for the better part of the last four months. The DJTA has finally broken free from the confines of its multi-month holding pattern, however. In today’s commentary I’ll explain why this bodes well for the interim outlook and why the Dow Industrials will soon follow the Transports higher. (8-0)
General Electric Company’s (GE - Free Report) unit GE Digital formed a strategic partnership with SIG to drive digital innovation in food and beverage packaging. SIG is an established provider of packaging systems and solutions for the food and beverage industry. (28-0)
After a century of being dormant, professional baseball appears open to the concept of two-way players. And that’s exactly how I view General Electric Company (NYSE:GE), as a two-way investment. In recent years, GE stock has provided ample profits for both bulls and bears. The difficulty, of course, is determining which side will show up. (41-0)
Wabtec was a logical buyer of GE's Transportation assets and the combined companies will have a lot to offer the rail operators of the world, including more digital/automation products. (16-0)
as of ET